Patent ID: 11919929

Abstract:
The invention provides for the expression and purification of a recombinant form of FABP (Fh15) exhibiting a similar suppressive effect on TLR-stimulation and inflammatory cytokine expression from macrophages than those previously demonstrated for the native molecule. Fh15 suppresses the expression of IL-1β and TNFα in murine macrophages and THP1 Blue CD14 cells. Additionally, Fh15 suppress the LPS-induced TLR4 stimulation. This effect was not impaired by a thermal denaturing process or blocked by the presence of anti-Fh12 antibodies. Fh15 also suppressed the stimulation of various TLRs in response to whole bacteria extracts so that Fh15 could be an excellent alternative for an anti-inflammatory drug in preclinical studies in the near future.